QTTB

Q32 Bio demonstrated strong Phase 2a efficacy for bempikibart in severe alopecia areata with a 35.3% mean SALT-score reduction, secured FDA Fast Track designation, raised ~$200M, and attracted multiple bullish analyst initiations with price targets ranging from $29–$42. The company simultaneously strengthened leadership with new CMO and CDO appointments to advance toward late-stage development.